Comments
Loading...
Nascent Biotech Analyst Ratings and Price Targets | OTC:NBIO | Benzinga
Nascent Biotech Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Nascent Biotech Corp from these most-recent analyst ratings.
Analyst Ratings for Nascent Biotech
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Nascent Biotech (NBIO) stock?
There is no price target for Nascent Biotech
What is the most recent analyst rating for Nascent Biotech (NBIO)?
There is no analyst for Nascent Biotech
When was the last upgrade for Nascent Biotech (NBIO)?
There is no last upgrade for Nascent Biotech
When was the last downgrade for Nascent Biotech (NBIO)?
There is no last downgrade for Nascent Biotech.
When is the next analyst rating going to be posted or updated for Nascent Biotech (NBIO)?
There is no next analyst rating for Nascent Biotech.
Is the Analyst Rating Nascent Biotech (NBIO) correct?
There is no next analyst rating for Nascent Biotech.
Browse analyst ratings and price targets on all stocks.
